Cargando…
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience
Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the sys...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226822/ https://www.ncbi.nlm.nih.gov/pubmed/32272732 http://dx.doi.org/10.3390/cells9040903 |
_version_ | 1783534370205728768 |
---|---|
author | Califano, Daniela Russo, Daniela Scognamiglio, Giosuè Losito, Nunzia Simona Spina, Anna Bello, Anna Maria Capiluongo, Anna Galdiero, Francesca De Cecio, Rossella Bevilacqua, Simona Gargiulo, Piera Marchesi, Edoardo Canevari, Silvana Perrone, Francesco Daniele, Gennaro De Cecco, Loris Mezzanzanica, Delia Pignata, Sandro |
author_facet | Califano, Daniela Russo, Daniela Scognamiglio, Giosuè Losito, Nunzia Simona Spina, Anna Bello, Anna Maria Capiluongo, Anna Galdiero, Francesca De Cecio, Rossella Bevilacqua, Simona Gargiulo, Piera Marchesi, Edoardo Canevari, Silvana Perrone, Francesco Daniele, Gennaro De Cecco, Loris Mezzanzanica, Delia Pignata, Sandro |
author_sort | Califano, Daniela |
collection | PubMed |
description | Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the systematic inclusion of translational analyses into the design of clinical trials. In the era of personalized medicine, the prospective centralized collection of high-quality biological material, expert pathological revision, and association to well-controlled clinical data are important or even essential added values to clinical trials. Here, we present the academic experience of the MITO (Multicenter Italian Trial in Ovarian Cancer) group, including gynecologists, pathologists, oncologists, biostatisticians, and translational researchers, whose effort is dedicated to the care and basic/translational research of gynecologic cancer. In our ten years of experience, we have been able to collect and process, for translational analyses, formalin-fixed, paraffin-embedded blocks from more than one thousand ovarian cancer patients. Standard operating procedures for collection, shipping, and processing were developed and made available to MITO researchers through the coordinating center’s web-based platform. Clinical data were collected through dedicated electronic case report forms hosted in a web-based electronic platform and stored in a central database at the trial’s coordinating center, which performed all the analyses related to the proposed translational researches. During this time, we improved our strategies of block management from retrospective to prospective collection, up to the design of a prospective collection with a quality check for sample eligibility before patients’ accrual. The final aim of our work is to share our experience by suggesting a guideline for the process of centralized collection, revision processing, and storing of formalin-fixed, paraffin-embedded blocks for translational purposes. |
format | Online Article Text |
id | pubmed-7226822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72268222020-05-18 Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience Califano, Daniela Russo, Daniela Scognamiglio, Giosuè Losito, Nunzia Simona Spina, Anna Bello, Anna Maria Capiluongo, Anna Galdiero, Francesca De Cecio, Rossella Bevilacqua, Simona Gargiulo, Piera Marchesi, Edoardo Canevari, Silvana Perrone, Francesco Daniele, Gennaro De Cecco, Loris Mezzanzanica, Delia Pignata, Sandro Cells Article Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers are clinically available. Improvement in biomarker selection and validation may derive from the systematic inclusion of translational analyses into the design of clinical trials. In the era of personalized medicine, the prospective centralized collection of high-quality biological material, expert pathological revision, and association to well-controlled clinical data are important or even essential added values to clinical trials. Here, we present the academic experience of the MITO (Multicenter Italian Trial in Ovarian Cancer) group, including gynecologists, pathologists, oncologists, biostatisticians, and translational researchers, whose effort is dedicated to the care and basic/translational research of gynecologic cancer. In our ten years of experience, we have been able to collect and process, for translational analyses, formalin-fixed, paraffin-embedded blocks from more than one thousand ovarian cancer patients. Standard operating procedures for collection, shipping, and processing were developed and made available to MITO researchers through the coordinating center’s web-based platform. Clinical data were collected through dedicated electronic case report forms hosted in a web-based electronic platform and stored in a central database at the trial’s coordinating center, which performed all the analyses related to the proposed translational researches. During this time, we improved our strategies of block management from retrospective to prospective collection, up to the design of a prospective collection with a quality check for sample eligibility before patients’ accrual. The final aim of our work is to share our experience by suggesting a guideline for the process of centralized collection, revision processing, and storing of formalin-fixed, paraffin-embedded blocks for translational purposes. MDPI 2020-04-07 /pmc/articles/PMC7226822/ /pubmed/32272732 http://dx.doi.org/10.3390/cells9040903 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Califano, Daniela Russo, Daniela Scognamiglio, Giosuè Losito, Nunzia Simona Spina, Anna Bello, Anna Maria Capiluongo, Anna Galdiero, Francesca De Cecio, Rossella Bevilacqua, Simona Gargiulo, Piera Marchesi, Edoardo Canevari, Silvana Perrone, Francesco Daniele, Gennaro De Cecco, Loris Mezzanzanica, Delia Pignata, Sandro Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience |
title | Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience |
title_full | Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience |
title_fullStr | Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience |
title_full_unstemmed | Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience |
title_short | Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience |
title_sort | ovarian cancer translational activity of the multicenter italian trial in ovarian cancer (mito) group: lessons learned in 10 years of experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226822/ https://www.ncbi.nlm.nih.gov/pubmed/32272732 http://dx.doi.org/10.3390/cells9040903 |
work_keys_str_mv | AT califanodaniela ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT russodaniela ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT scognamigliogiosue ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT lositonunziasimona ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT spinaanna ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT belloannamaria ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT capiluongoanna ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT galdierofrancesca ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT dececiorossella ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT bevilacquasimona ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT gargiulopiera ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT marchesiedoardo ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT canevarisilvana ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT perronefrancesco ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT danielegennaro ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT dececcoloris ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT mezzanzanicadelia ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience AT pignatasandro ovariancancertranslationalactivityofthemulticenteritaliantrialinovariancancermitogrouplessonslearnedin10yearsofexperience |